Alliance Global Partners slashed its price target for ReShape Lifesciences (NASDAQ:RSLS) to $5.50 from $10.25 but maintained its “buy” rating, citing the company’s fourth quarter results. The stock closed at $1.35 on...
Alliance Global Partners raised its price target for ReShape Lifesciences (NASDAQ:RSLS) to $18.50 from $12, citing an improved outlook and lower-than-anticipated share count following it’s merger with Obalon...